Comment on "Proposal for Diagnostic Criteria for Manifestations of Chronic Graft-versus-Host Disease in the Central Nervous System" [0.03%]
关于“慢性移植物抗宿主病中枢神经系统表现诊断标准建议”的评论
Mohammed Razia Alangir Banu,Dr Sumit Hazra,A S Gousia Banu
Mohammed Razia Alangir Banu
Large B-Cell Lymphoma After CD19 CAR-T Failure: Updated Real-World Outcomes, Prognostic Factors, and Prediction Models [0.03%]
CD19 CAR-T治疗失败后的大B细胞淋巴瘤：更新的实际疗效、预后因素和预测模型
Smith Kungwankiattichai,Sanjog Bastola,Manoj Rai et al.
Smith Kungwankiattichai et al.
Background Outcomes after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy failure in relapsed or refractory large B-cell lymphoma (LBCL) remain poor, and prognostic tools to guide subsequent management are limited. We evaluat...
Impact of Prior Bendamustine Exposure on Chimeric Antigen Receptor T-Cell Therapy Outcomes in Follicular Lymphoma [0.03%]
既往苯达莫司汀治疗对套细胞淋巴瘤患者CAR-T疗效影响的研究
Danielle DeCicco,Sanjana Nethagani,Shanawar Waris et al.
Danielle DeCicco et al.
Prior bendamustine exposure impairs T-cell fitness and has been associated with inferior CAR T-cell therapy outcomes in large B-cell lymphoma, but follicular lymphoma (FL)-specific data are lacking. Using the TriNetX Research Network (107 h...
Body mass index and outcomes after CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphoma: a nationwide registry study [0.03%]
身体质量指数与CD19 CAR T细胞治疗后复发/难治性B细胞淋巴瘤的预后：一项全国登记处研究
Tatsuya Konishi,Wataru Kitamura,Shohei Mizuno et al.
Tatsuya Konishi et al.
Chimeric antigen receptor (CAR) T-cell therapy is effective for treating relapsed or refractory B-cell lymphoma; however, its outcomes remain heterogeneous. We conducted a nationwide retrospective registry study in Japan to assess whether p...
Serum-Free Expanded Hair Follicle Mesenchymal Stem Cells Promote Cartilage Repair in a Murine Full-Thickness Defect Model [0.03%]
无血清条件下扩增的毛乳头间充质干细胞促进小鼠全层软骨缺损修复中的作用研究
HaoChen Sun,Emilie Gysel,Leila Larijani et al.
HaoChen Sun et al.
▒: Serum-free expanded hair follicle mesenchymal stem cells (hfMSCs) maintained mesenchymal phenotype and multipotency during static and stirred suspension bioreactor (SSB) expansion and promoted histological cartilage repair in a murine f...
Toward Standardized Screening for Chronic GVHD: Insights from the Engraft Learning Network [0.03%]
向慢性GVHD的标准化筛查迈进：来自Engraft学习网络的见解
Laila Alkhouli,Seth Rotz,Christopher Dandoy et al.
Laila Alkhouli et al.
Background: Chronic graft-versus-host disease (cGVHD) affects up to 54% of allogeneic hematopoietic cell transplantation (HCT) recipients and is the leading cause of late non-relapse morbidity and mortality. Despite the a...
Enumeration of CD34-CD133+ Haematopoietic Progenitor Cells in Cord Blood [0.03%]
脐带血中CD34-CD133+造血祖细胞的检测 Enumeration of CD34-CD133+ Haematopoietic Progenitor Cells in Cord Blood
Guy Klamer,Kap-Hyoun Ko
Guy Klamer
Background: Cord blood unit (CBU) selection for allogeneic haematopoietic stem cell transplantation relies heavily on haematopoietic progenitor cell (HPC) enumeration, with CD34+ dose strongly associated with engraftment ...
Haploidentical hematopoietic stem cell transplantation drives time-dependent premature T cell senescence: Recipient microenvironment modulates donor T cell epigenetic aging, telomere homeostasis and SASP remodeling [0.03%]
单倍体相合造血干细胞移植诱导时间依赖性的T细胞衰老：宿主微环境调节供者T细胞表观遗传学老化、端粒平衡和分泌衰老相关分泌表型的重塑
Lin Sun,Yichen Zhang,Hong Zhang et al.
Lin Sun et al.
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) cures hematological malignancies but severely impairs long-term immune reconstitution by inducing T cell senescence. Previous studies have linked ...
Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data [0.03%]
阿西西莫珠单抗和倍西西莫珠单抗嵌合抗原受体T细胞治疗后细胞因子释放综合征及免疫效应细胞相关神经毒性综合症的中心国际血液与骨髓移植研究数据
Matthew J Frigault,Richard T Maziarz,Theresa Amoloja et al.
Matthew J Frigault et al.
Background: Chimeric antigen receptor T-cell (CAR-T) therapies targeting CD19 have demonstrated effectiveness in the treatment of relapsed/refractory B-cell malignancies. Several CAR-T therapies have been approved in the ...
From Algorithms to Intuition: Diversity of Donor Selection for Allogeneic HCT [0.03%]
从算法到直觉：allo-HCT供者选择的多样性
Arijit Nag,Pankaj Malhotra
Arijit Nag